The Role of ERα and ERβ in Castration-Resistant Prostate Cancer and Current Therapeutic Approaches

Abstract

Castration-resistant prostate cancer, or CRPC, is an aggressive stage of prostate cancer (PCa) in which PCa cells invade nearby or other parts of the body. When a patient with PCa goes through androgen deprivation therapy (ADT) and the cancer comes back or worsens, this is called CRPC. Instead of androgen-dependent signalling, recent studies show the involvement of the estrogen pathway through the regulation of estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ) in CRPC development. Reduced levels of testosterone due to ADT lead to low ERβ functionality in inhibiting the proliferation of PCa cells. Additionally, ERα, which possesses androgen independence, continues to promote the proliferation of PCa cells. The functions of ERα and ERβ in controlling PCa progression have been studied, but further research is needed to elucidate their roles in promoting CRPC. Finding new ways to treat the disease and stop it from becoming worse will require a clear understanding of the molecular processes that can lead to CRPC. The current review summarizes the underlying processes involving ERα and ERβ in developing CRPC, including castration-resistant mechanisms after ADT and available medication modification in mitigating CRPC progression, with the goal of directing future research and treatment.

Increased Age-Adjusted Cancer Mortality After the Third mRNA-Lipid Nanoparticle Vaccine Dose During the COVID-19 Pandemic in Japan

“…In our study, the AMRs of ovarian cancer, leukemia, prostate, lip/oral/pharyngeal, pancreatic, and breast cancers increased significantly beyond the predicted rates, especially in 2022. All of these cancers are known as estrogen and estrogen receptor alpha (ERα)-sensitive cancers [78][79][80][81][82][83]. Recent research by Solis et al on the binding ability of S-protein of SARS-CoV-2 against over 9,000 human proteins has shown that S-protein specifically binds to ERα and upregulates the transcriptional activity of ERα.…”

Therapeutic targets of formononetin for treating prostate cancer at the single-cell level

“…For instance, the activation of ERα and ERβ promoted the migration, cell invasion and colony formation abilities in hormone-independent prostate cancer cells [ 10 ]. In addition, the development of prostate cancer into denuded resistant prostate cancer is mediated by ERα and ERβ [ 11 ]. So, targeting ER could be an option for discovery of novel compound for treating prostate cancer.…”

Atractylenolide I ameliorated the progression of CRPC by suppressing KIF15/AR/AR-V7 signaling

“…Given the importance of the androgen receptor (AR) pathway in PCa development and progression, androgen deprivation therapy (ADT) has been perceived as the firstline therapeutic strategy against PCa [3]. Although these advances provided temporary respite, most patients inevitably develop a lethal form called metastatic castrationresistant prostate cancer (mCRPC), with a median survival of about 3 years [4], which remains a critical clinical challenge.…”